Primary Myelofibrosis (PMF) Clinical Trial
Official title:
A PhaseI/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 Inhibitor AZD1480 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF
This study is being conducted to test study drug AZD1480 to see how it may work to treat myeloproliferative diseases. The main purpose of this study is to determine the safety and tolerability of AZD1480. This is the first time the drug has been given to humans and is classed as a first time in man study. Its main purpose is to establish a safe dosage of the drug and provide additional information on any potential side effects this drug may cause. The study will also assess the blood levels and action of AZD1480 in the body over a period of time and will indicate whether the drug has a therapeutic effect on myeloproliferative diseases.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03441113 -
Extended Access of Momelotinib in Adults With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT01558739 -
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
|
Phase 4 | |
| Completed |
NCT02101268 -
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
|
Phase 3 | |
| Completed |
NCT03136185 -
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
|
Phase 1/Phase 2 | |
| Completed |
NCT04217993 -
Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
|
Phase 2 | |
| Completed |
NCT02515630 -
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
|
Phase 2 | |
| Recruiting |
NCT03662126 -
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
|
Phase 2/Phase 3 | |
| Terminated |
NCT03935555 -
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
|
Phase 1 | |
| Recruiting |
NCT04878003 -
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
|
Phase 2 | |
| Available |
NCT04745637 -
Managed Access Programs for INC424, Ruxolitinib
|